Home / Top News / Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the 2021 Transplantation and Cellular Therapy Meetings Digital Experience
Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the 2021 Transplantation and Cellular Therapy Meetings Digital Experience
Higher dose cohorts demonstrated 100% overall response rate, resulting in substantial
reduction in baseline corticosteroid use
Dose-dependent reduction of CD6 expression on CD4+ and CD8+ T cells is consistent with itolizumab mechanism of action
LA JOLLA, Calif., Feb. 12, 2021 (GLOBE NEWSWIRE) Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, presented interim data from the EQUATE clinical trial supporting itolizumab’s potential as a first-line treatment for acute g
Imago BioSciences Appoints Enoch Kariuki to Board of Directors
Imago BioSciences Appoints Enoch Kariuki to Board of Directors
Imago BioSciences, Inc. (Imago), a clinical stage biopharmaceutical company developing innovative treatments for myeloid diseases, today announced that its board has appointed a new independent director, Enoch Kariuki, PharmD., who most recently served as the chief financial officer of VelosBio. Enoch comes to Imago with significant expertise in capital formation, business development and finance, and Im delighted to strengthen our board with his addition, said Hugh Rienhoff, Jr., M.D., chief executive officer, Imago BioSciences. His perspective as both an investor and executive in the biotechnology field will provide our board with valuable insights to propel Imago through its upcoming corporate and clinical development milestones.
Taysha Gene Therapies Continues to Add Significant Gene Therapy Expertise to Leadership Team with the Appointment of Chief Legal Officer and Chief People Officer manchestertimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from manchestertimes.com Daily Mail and Mail on Sunday newspapers.
Posted on 344
MBX Biosciences, a drug discovery company focused on rare endocrine diseases, today announced the appointment of Mary Jane Geiger, M.D., Ph.D., FACP, FAHA, to the newly created role of chief medical officer. Dr. Geiger will oversee MBX’s global clinical drug development, bringing more than 20 years’ experience in clinical drug development and supporting multiple successful drug registrations.
“Mary Jane’s range of experience taking treatments through clinical studies to registration makes her an ideal addition to our team,” said Kent Hawryluk, president and chief executive officer of MBX Biosciences. “Her demonstrated creativity in clinical trial design and strong clinical research background complement our organization’s expertise. She will play a leading role in MBX’s transition into a clinical-stage company.”
Biocom Institute Launches Largest Diversity, Equity and Inclusion Report in California’s Life Science Industry
Biocom Institute Launches Largest Diversity, Equity and Inclusion Report in California’s Life Science Industry Biocom Institute, a 501(c)(3) non-profit that supports life science innovation by strengthening the workforce and leaders of tomorrow, launched its first biennial report, Diversity, Equity and Inclusion in Californias Life Science Industry. With more than 350 respondents, this report represents the most comprehensive diversity, equity and inclusion (DEI) data gathered across life science companies in California “ providing a framework for the industry to develop an actionable DEI plan. Additional life science organizations Thermo Fisher Scientific, Bayer Pharmaceuticals and Biocom California contributed to developing the report.